Overview

Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of new tablet formulations of Premarin®/medroxyprogesterone (MPA).
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborator:
MDS Pharma Services
Treatments:
Estrogens, Conjugated (USP)
Medroxyprogesterone
Medroxyprogesterone Acetate